Sodium bicarbonate therapy for critically ill patients with metabolic acidosis: A scoping and a systematic review

Research output: Contribution to journalArticleResearchpeer-review

3 Citations (Scopus)

Abstract

Purpose: We aimed to assess the biochemical and physiological effects, clinical efficacy, and safety, of intravenous NaHCO3 therapy in critically ill patients with acute metabolic acidosis. Methods: We conducted a scoping review concerning the biochemical and physiological effects of NaHCO3 (PART A), and a systematic review regarding clinical efficacy (PART B). We searched MEDLINE in Part A and MEDLINE, EMBASE, Cochrane, the National Institute of Health Clinical Trials Register, and the WHOICTRP for randomised controlled trials in Part B. Results: Twelve studies in Part A and two trials in Part B fulfilled the eligibility criteria. Intravenous NaHCO3 increased blood pH, base excess, serum bicarbonate, sodium, and PaCO2 during and after administration and decreased anion gap and potassium value. For clinical efficacy, only one study contributed to the effect estimate. The risk ratio (RR) for all-cause mortality was 0.83 (95% confidence interval, 0.68 to 1.02), and the risk of hypocalcaemia was increased in the bicarbonate group (RR 1.65, 95% confidence interval 1.09 to 2.50). There were inadequate data on hemodynamic indices. Conclusions: Given the lack of data on the effects of intravenous NaHCO3 therapy to support its clinical use and the frequency of bicarbonate therapy, a program of investigation appears justified.

Original languageEnglish
Pages (from-to)184-191
Number of pages8
JournalJournal of Critical Care
Volume51
DOIs
Publication statusPublished - 1 Jun 2019

Keywords

  • Intensive care
  • Metabolic acidosis
  • Sodium bicarbonate
  • Systematic review

Cite this

@article{c4e7d2436d8440be8d85142e62910127,
title = "Sodium bicarbonate therapy for critically ill patients with metabolic acidosis: A scoping and a systematic review",
abstract = "Purpose: We aimed to assess the biochemical and physiological effects, clinical efficacy, and safety, of intravenous NaHCO3 therapy in critically ill patients with acute metabolic acidosis. Methods: We conducted a scoping review concerning the biochemical and physiological effects of NaHCO3 (PART A), and a systematic review regarding clinical efficacy (PART B). We searched MEDLINE in Part A and MEDLINE, EMBASE, Cochrane, the National Institute of Health Clinical Trials Register, and the WHOICTRP for randomised controlled trials in Part B. Results: Twelve studies in Part A and two trials in Part B fulfilled the eligibility criteria. Intravenous NaHCO3 increased blood pH, base excess, serum bicarbonate, sodium, and PaCO2 during and after administration and decreased anion gap and potassium value. For clinical efficacy, only one study contributed to the effect estimate. The risk ratio (RR) for all-cause mortality was 0.83 (95{\%} confidence interval, 0.68 to 1.02), and the risk of hypocalcaemia was increased in the bicarbonate group (RR 1.65, 95{\%} confidence interval 1.09 to 2.50). There were inadequate data on hemodynamic indices. Conclusions: Given the lack of data on the effects of intravenous NaHCO3 therapy to support its clinical use and the frequency of bicarbonate therapy, a program of investigation appears justified.",
keywords = "Intensive care, Metabolic acidosis, Sodium bicarbonate, Systematic review",
author = "Tomoko Fujii and Andrew Udy and Elisa Licari and Lorena Romero and Rinaldo Bellomo",
year = "2019",
month = "6",
day = "1",
doi = "10.1016/j.jcrc.2019.02.027",
language = "English",
volume = "51",
pages = "184--191",
journal = "Journal of Critical Care",
issn = "0883-9441",
publisher = "Elsevier",

}

Sodium bicarbonate therapy for critically ill patients with metabolic acidosis : A scoping and a systematic review. / Fujii, Tomoko; Udy, Andrew; Licari, Elisa; Romero, Lorena; Bellomo, Rinaldo.

In: Journal of Critical Care, Vol. 51, 01.06.2019, p. 184-191.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Sodium bicarbonate therapy for critically ill patients with metabolic acidosis

T2 - A scoping and a systematic review

AU - Fujii, Tomoko

AU - Udy, Andrew

AU - Licari, Elisa

AU - Romero, Lorena

AU - Bellomo, Rinaldo

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose: We aimed to assess the biochemical and physiological effects, clinical efficacy, and safety, of intravenous NaHCO3 therapy in critically ill patients with acute metabolic acidosis. Methods: We conducted a scoping review concerning the biochemical and physiological effects of NaHCO3 (PART A), and a systematic review regarding clinical efficacy (PART B). We searched MEDLINE in Part A and MEDLINE, EMBASE, Cochrane, the National Institute of Health Clinical Trials Register, and the WHOICTRP for randomised controlled trials in Part B. Results: Twelve studies in Part A and two trials in Part B fulfilled the eligibility criteria. Intravenous NaHCO3 increased blood pH, base excess, serum bicarbonate, sodium, and PaCO2 during and after administration and decreased anion gap and potassium value. For clinical efficacy, only one study contributed to the effect estimate. The risk ratio (RR) for all-cause mortality was 0.83 (95% confidence interval, 0.68 to 1.02), and the risk of hypocalcaemia was increased in the bicarbonate group (RR 1.65, 95% confidence interval 1.09 to 2.50). There were inadequate data on hemodynamic indices. Conclusions: Given the lack of data on the effects of intravenous NaHCO3 therapy to support its clinical use and the frequency of bicarbonate therapy, a program of investigation appears justified.

AB - Purpose: We aimed to assess the biochemical and physiological effects, clinical efficacy, and safety, of intravenous NaHCO3 therapy in critically ill patients with acute metabolic acidosis. Methods: We conducted a scoping review concerning the biochemical and physiological effects of NaHCO3 (PART A), and a systematic review regarding clinical efficacy (PART B). We searched MEDLINE in Part A and MEDLINE, EMBASE, Cochrane, the National Institute of Health Clinical Trials Register, and the WHOICTRP for randomised controlled trials in Part B. Results: Twelve studies in Part A and two trials in Part B fulfilled the eligibility criteria. Intravenous NaHCO3 increased blood pH, base excess, serum bicarbonate, sodium, and PaCO2 during and after administration and decreased anion gap and potassium value. For clinical efficacy, only one study contributed to the effect estimate. The risk ratio (RR) for all-cause mortality was 0.83 (95% confidence interval, 0.68 to 1.02), and the risk of hypocalcaemia was increased in the bicarbonate group (RR 1.65, 95% confidence interval 1.09 to 2.50). There were inadequate data on hemodynamic indices. Conclusions: Given the lack of data on the effects of intravenous NaHCO3 therapy to support its clinical use and the frequency of bicarbonate therapy, a program of investigation appears justified.

KW - Intensive care

KW - Metabolic acidosis

KW - Sodium bicarbonate

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85062448124&partnerID=8YFLogxK

U2 - 10.1016/j.jcrc.2019.02.027

DO - 10.1016/j.jcrc.2019.02.027

M3 - Article

C2 - 30852347

AN - SCOPUS:85062448124

VL - 51

SP - 184

EP - 191

JO - Journal of Critical Care

JF - Journal of Critical Care

SN - 0883-9441

ER -